Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of pegylated liposomal doxorubicin versus carboplatin + paclitaxel sequencing in partially platinum-sensitive recurrent ovarian cancer
2008-001755-22Phase 3Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Feb 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, carboplatin and paclitaxel in ovarian cancer and recurrent ovarian cancer (ROC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: overall survival. Started Feb 2009; status: completed.
02
Drugs
doxorubicincarboplatinpaclitaxel
03
Conditions
ovarian cancerrecurrent ovarian cancer (ROC)
Beyond the preview
Go deeper on 2008-001755-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001755-22.